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The adhesion and aggregation of platelets during hemostasis and thrombosis represents one
of the best-understood examples of cell–matrix adhesion. Platelets are exposed to a wide
variety of extracellular matrix (ECM) proteins once blood vessels are damaged and basement
membranes and interstitial ECM are exposed. Platelet adhesion to these ECM proteins
involves ECM receptors familiar in other contexts, such as integrins. The major platelet-
specific integrin, aIIbb3, is the best-understood ECM receptor and exhibits the most tightly
regulated switch between inactive and active states. Once activated, aIIbb3 binds many
different ECM proteins, including fibrinogen, its major ligand. In addition to aIIbb3, there
are other integrins expressed at lower levels on platelets and responsible for adhesion to
additional ECM proteins. There are also some important nonintegrin ECM receptors, GPIb-
V-IX and GPVI, which are specific to platelets. These receptors play major roles in platelet
adhesion and in the activation of the integrins and of other platelet responses, such as
cytoskeletal organization and exocytosis of additional ECM ligands and autoactivators of
the platelets.
The balance between hemostasis and throm-bosis relies on a finely tuned adhesive
response of blood platelets. Inadequate adhe-
sion leads to bleeding, whereas excessive or
inappropriate adhesion leads to thrombosis.
Resting platelets are nonadhesive anuclear discs
and do not interact with the vessel wall, but
they have a plethora of receptors that sense
activating signals (agonists) of various sorts.
The activating signals include soluble factors
such as thrombin, adenosine diphosphate
(ADP), and epinephrine, all of which act on
G-protein-coupled receptors (GPCRs) on the
platelets. In addition, certain receptors for
extracellular matrix (ECM) proteins (e.g.,
GPIb, GPVI, and some integrins) can also act
as activating receptors. These diverse receptors
trigger intracellular signaling pathways that
activate (1) actin assembly leading to cell
shape change and extension of filopodia; (2)
exocytosis of secretory granules that release
additional platelet agonists as well as adhesive
ECM proteins; and (3) activation of addi-
tional cell-surface receptors such as the major
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platelet-specific integrin, aIIbb3, that contrib-
ute further to the adhesion and aggregation of
activated platelets. Thus, the interactions of
platelet-ECM adhesion receptors with ECM
proteins from the vessel wall, from the plasma,
and from the platelets themselves, are central
to both the initial adhesion and the subsequent
activation and aggregation of platelets (Varga-
Szabo et al. 2008). These adhesive interactions,
together with coagulation (to which platelets
also contribute), generate the fibrin clot, essen-
tially a facultative ECM that forms the initial
occlusion of the damaged vessel but also serves
as a subsequent ECM substrate for wound heal-
ing. In this article, we will review what is known
about the roles of ECM proteins and their
receptors in platelet adhesion and aggregation,
summarize the roles of the clot and provisional
ECM in subsequent wound healing, point out
various unanswered questions, and discuss
briefly the contributions of the relevant cell–
ECM interactions to disease and the potential
for therapeutic interventions.
THE ENDOTHELIUM, THE BASEMENT
MEMBRANE, AND THE ECM OF THE
VESSEL WALL
Blood vessels are lined by a monolayer of endo-
thelial cells, which form adhesion complexes,
including tight junctions, sealing the lumen of
the vessels from the underlying basement mem-
brane and interstitial matrix. The apical surfaces
of quiescent endothelial cells in undamaged and
noninflamed vessels are nonadhesive to circu-
lating cells, including platelets. This is both
because of the nature of their plasma membrane
and cell-surface proteins, including an extensive
glycocalyx, and to the fact that the apical sur-
faces lack any ECM. Endothelial cells actively
synthesize ECM proteins but they deposit
them basally or retain them in secretory gran-
ules, known as Weibel-Palade bodies. Beneath
the endothelial cell layer is a basement mem-
brane, which like other basement membranes
contains type IV collagen, laminins, nidogens,
and perlecan (Yurchenco 2011). The predomi-
nant isoforms in vascular basement membranes
are nidogen 2 and laminins 8 and 10 (laminins
411 and 511), although there is some variation
among vascular beds (Hallmann et al. 2005).
Whether or not the collagen IV isoforms vary
has not been investigated. Unlike other base-
ment membranes, the endothelial basement
membrane also contains von Willebrand factor,
a large ECM protein produced only by endo-
thelial cells and the megakaryocyte/platelet
lineage. Von Willebrand factor (VWF) plays a
crucial role in hemostasis and thrombosis (see
below). In angiogenic vessels, fibronectin is
also a prominent constituent of the endothelial
basement membrane, although it is found at
lower levels in quiescent vessels. In addition to
the change in level, the splice isoforms of fibro-
nectin differ between angiogenic and quiescent
vessels—the former contain the alternatively
spliced EIIIA and EIIIB domains (Schwarz-
bauer and DeSimone 2011), whereas the latter
do not. Both the levels of fibronectin and the
inclusion of these two splice segments are also
elevated in vessels during atherosclerosis and
after myocardial infarction or wound healing,
and probably in other situations in which the
endothelial cells are activated (Astrof and Hynes
2009). In addition, certain other ECM proteins
are found in certain vascular beds (Hallmann
et al. 2005). Thus, the ECM proteins in the base-
ment membranes of different vessels can vary.
Beneath the intimal endothelial layer lie
smooth muscle cells (in large vessels) or peri-
cytes (in small vessels). Pericytes and endo-
thelial cells are invested within a common
basement membrane, whereas smooth muscle
cells in larger vessels form a separate, so-called
medial layer with its own extracellular matrix
components including elastin, collagens, and
fibrillin microfibrils (Wagenseil and Mecham
2009). Arteries have more smooth muscle
cell layers and more elastin than do veins. Out-
side the smooth muscle cell layer of large
vessels, there is an adventitial layer containing
fibroblasts, fibrillar collagens, fibronectin, and
many other ECM proteins. The environment
beyond the adventitium of large vessels or
the pericyte layer of small vessels varies with
the tissue. In brain vessels there is a closely
apposed layer of astrocyte end-feet surrounding
the vascular unit, which contributes to the
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blood–brain barrier and has a separate and dis-
tinct basement membrane of its own (Sixt et al.
2001). Many other small vessels (arterioles,
venules, and capillaries) are surrounded by an
interstitial matrix, again containing fibrillar
collagens, fibronectin, and other ECM proteins.
In the interstitium, fibrillar collagen types I, III,
and V are the most prominent (Voss and Rau-
terberg 1986). Therefore, the ECM proteins to
which platelets and leukocytes become exposed
depend both on the degree of injury to the ves-
sels and on the type of vessel involved (Fig. 1).
Mild injuries such as damage to the endothelial
layer will expose type IV collagen, laminins, and
VWF, and in some situations, fibronectins,
whereas more extensive injuries exposing the
smooth muscle layer or interstitial ECM will
expose them in addition to fibrillar collagens,
elastin, microfibrils, and other ECM proteins.
PLATELET-ECM INTERACTIONS: INITIAL
PLATELET ADHESION
In this section, we will summarize our under-
standing of the molecular mechanisms by which































Figure 1. ECM protein sources for hemostasis. Platelets have access to a wide variety of ECM proteins with which
to interact. Multiple ECM proteins circulate in plasma, the most important for hemostasis being VWF and fibri-
nogen. Platelets themselves have multiple ECM proteins stored in secretory a granules, which release their con-
tents on platelet activation; some of these secreted platelet-ECM proteins are released as soluble proteins, others
are retained at the surfaces of the activated platelets, often by interactions with platelet adhesion receptors. The
lumenal surfaces of endothelial cells (green) are free of ECM, but the basement membrane beneath them (gray)
contains the usual basement membrane proteins plus VWF. Basement membranes of some vessels also contain
additional ECM proteins. The layers below the basement membrane vary with vessel type; shown here are a
smooth muscle layer (red) containing elastin, microfibrils, collagens, and fibronectin, and the surrounding con-
nective tissue adventitial layer (black), which contains fibrillar collagens, fibronectin, and other ECM proteins.
The interstitium around blood vessels (gray mesh) obviously varies with the tissue but typically contains fibrillar
collagens, fibronectin, and diverse other ECM proteins. Therefore, the ECM proteins available to mediate
platelet adhesion vary greatly depending on the vessels involved and on the severity of the injury (e.g., whether
or not ECM below the basement membrane is exposed). The ECM also evolves considerably during the course of
a hemostatic or thrombotic event. Circulating VWF can be bound directly by platelets or can bind to exposed
collagen fibers. Platelet activation, either by soluble factors such as thrombin, ADP, and epinephrine or by ECM
proteins such as VWF, collagens, and laminins, releases additional ECM proteins and activates receptors that can
recruit additional ECM proteins such as fibrinogen. Platelets have receptors for many, maybe all, of these ECM
proteins and a reasonable hypothesis is that they have evolved to adhere to whatever ECM proteins they encoun-
ter, no matter where the lesion occurs or how severe the injury. ECM proteins known to have major roles in
platelet adhesion and aggregation are bolded.
Extracellular Matrix Proteins in Hemostasis and Thrombosis
Cite this article as Cold Spring Harb Perspect Biol 2012;4:a005132 3
their responses to these interactions. Platelet
adhesion under arterial high shear conditions
(as in arteries) is a multistep process that
requires interaction of various receptors, some
generic and some platelet-specific, with their
ligands in the ECM (Varga-Szabo et al. 2008).
A critical step in the adhesion response is the
tethering of platelets to VWF present in the
ECM. This initial adhesion step is mediated
with a high on-rate by the constitutively active
platelet-specific receptor for VWF, GPIb-V-IX.
This interaction is reversible and leads to rolling
or sliding of the platelets along the exposed
VWF-rich ECM, which can be the exposed
endothelial basement membrane or fibrillar col-
lagen to which circulating VWF has bound (see
below). Subsequent to GPIb-VWF-mediated
tethering, other platelet receptors with lower
on-rates but higher affinities can engage their
ligands expressed in the ECM. Arguably the
most important interactions at these early stages
are those of collagen with GPVI, a member of the
immunoglobulin superfamily, and with integrin
a2b1. Another significant interaction is pro-
vided by laminin binding to GPVI and integrin
a6b1. Especially when activated by collagen,
GPVI provides stimulatory signals, which trigger
various platelet responses such as activation of
aIIbb3 integrin, granule release, the generation
of lipid mediators, cytoskeletal rearrangements,
and surface exposure of procoagulant phos-
phatidylserine. Engagement of platelet aIIbb3
integrin is crucial for firm platelet adhesion to
the substrate, for platelet aggregation, and also
for strengthening of the stimulatory signal owing
to integrin outside-in signaling (see below).
VWF
VWF is a glycoprotein constituent of the vascu-
lar basement membrane and also circulates in
plasma as large multimers ranging from 500
to 10,000 kDa. The mature VWF monomer
consists of 2050 residues and contains a number
of domains important for the function of the
molecule, as well as cysteine residues for cross-
linking into dimers and multimers via disulfide
bonds (Fig. 2) (Wagner 1990; Ruggeri 1997;
Sadler 2009). Endothelial cells (ECs) and
megakaryocytes are the only cells that synthesize
VWF. In ECs, VWF is either constitutively
secreted or targeted to storage granules,
the Weibel-Palade bodies, for agonist-induced
secretion. In contrast, only agonist-induced
secretion from a granules is observed in plate-
lets. Consequently, plasma VWF is essentially
completely derived from ECs. VWF multimers
released from storage granules are extremely
large and designated as ULVWF (ultralarge
von Willebrand factor). ULVWF is biologically
hyperactive, as it forms stronger bonds with
its platelet receptor, GPIba (Arya et al. 2002),
presumably as a consequence of multipoint
binding, and it binds better to ECM than do
the typical smaller plasma multimers. Upon
secretion, ULVWF multimers are cleaved to
less active smaller-sized multimers by the
protease ADAMTS13 (a disintegrinlike and
metalloprotease with thrombospondin type I
repeats-13) under conditions of fluid shear
stress (see below). Deficiency of ADAMTS13
function—either familial (mutation in the
ADAMTS13 gene) or acquired (inhibitory anti-
bodies generated against ADAMTS13)—has
been linked to the pathogenesis of thrombotic
thrombocytopenic purpura (TTP), a disorder
of thrombotic microangiopathy (Levy et al.
2001; Lammle et al. 2005; Sadler 2008). Studies
in mice lacking ADAMTS-13 (Motto et al.
2005; Banno et al. 2006) confirmed previous
findings in patients (Furlan and Lammle 2001;
Veyradier et al. 2004), which suggested that
genetic and environmental factors, in addition
to ADAMTS13 deficiency, are required to trig-
ger TTP. In circulation, VWF binds noncova-
lently to coagulation factor VIII (FVIII), thus
protecting it from proteolysis. Consequently,
humans and mice lacking VWF are character-
ized by a marked decrease in plasma FVIII levels
and a significant increase in the “activated par-
tial thromboplastin time (aPTT),” a measure of
contact-phase-dependent coagulation (Weiss
et al. 1977; Denis et al. 1998). Thus, VWF facil-
itates primary adhesion (tethering) of platelets
to the exposed ECM and it efficiently localizes
FVIII to sites of vascular injury.
As mentioned, VWF is a constituent of
endothelial basement membranes and is also
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released by activated ECs or platelets. Its major
role in hemostasis and thrombosis occurs under
conditions of high shear, and the very large
size of VWF multimers plays an important
role in the sensitivity of VWF to shear. Several
of the interactions of VWF are subject to mod-
ulation by conformational changes in the three
VWA domains (A1,A2,A3) of VWF (see Fig. 2),
including mechanical deformation by shear
stress. The ultralarge multimers found in
TTP become extended under flow and bind
platelets through the constitutively active GPIb-
V-IX complex. Cleavage of the A2 domain by
ADAMTS13 requires shear to expose the cleav-
age site (Zhang et al. 2009; Zhou et al. 2010).
The smaller (but still large) multimers arising
after cleavage by ADAMTS13 bind through
the A3 domain to fibrillar collagens exposed
by injury, and this interaction plus shear forces
expose the A1 domain for interaction with
GPIba. Shear also enhances the interactions of
the A3 domain with collagen (Schneider et al.
2007) in part by exposing the A3 domain. Fur-
thermore, the VWF-A1/GPIba interaction is a
flex bond whose affinity increases under shear
stress (Kim et al. 2010).
* *
*
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Figure 2. von Willebrand factor. (A) Domain structure and binding sites of von Willebrand factor (VWF).
The standard domains (as per the SMART protein domain site http://smart.embl-heidelberg.de) are shown
in the diagram. In the hemostasis field, VWF is traditionally designated with A, B, C, and D repeats. The A
repeats correspond with VWA domains and each D repeat corresponds with a combination of tandem
VWD/C8/TIL domains. The carboxyl terminus of the molecule comprises three VWC domains and a carboxy-
terminal knot domain. These do not correspond exactly with the B and C repeats. The C8, TIL, VWC, and CT
domains are all cysteine-rich, making the drawing of boundaries between domains nontrivial; here we have used
the standard domains based on hidden Markov models and comparisons with other proteins. Binding sites are
shown for the coagulation cofactor, factor VIII (D3 repeat), for collagen (collagen binds the A3 domain) and for
the two major receptors for VWF, the GPIb-V-IX complex (A1 domain) and integrin aIIbb3 (an RGD site
between the last two VWC domains; see text). During biosynthesis and processing, the prodomain comprising
D1 and D2 repeats is separated from the mature VWF by cleavage after a dibasic amino acid pair by the enzyme
PACE (paired basic amino acid cleaving enzyme). VWF monomers then associate into dimers (500 kDa)
through disulfide bonding of their carboxy-terminal domains. (B) VWF multimerization. The tail–tail VWF
dimers then associate by amino-terminal disulfide bonding into ultralarge VWF polymers (.10 million Da;
.40 monomers) that are stored in Weibel-Palade bodies. When these are released, they form enormous
extended fibrils, which extend under the shear forces in the circulation and are cleaved by ADAMTS13 to smaller
but still large multimers containing fewer than 40 monomers. ADAMTS13 cleaves in the A2 VWA domain (see
text). (C) Domain key shows the domains making up VWF and other features such as intersubunit S—S bonds
and the integrin-binding RGD site.
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The GPIb-V-IX Receptor Complex
The GPIb-V-IX receptor complex consists of
four gene products: GPIba, GPIbb, GPIX, and
GPV in 2:4:2:1 ratios (Fig. 3) (Andrews et al.
2003; Luo et al. 2007; Bergmeier et al. 2008;
Clemetson and Clemetson 2008). The amino-
terminal region of GPIba, comprising eight
LRR repeats plus amino- and carboxy-terminal
caps, is the major ligand-binding domain for
VWF, but it also binds various other ligands





























Figure 3. Platelet receptors for ECM proteins. (A) The GPIb-V-IX complex—the major receptor for von Wille-
brand factor (VWF), which binds through its A1 VWA domain (blue pentagon) to the LRR repeat region of
GPIba. The receptor is constitutively active and has nine subunits: two copies of GPIba, each of which associates
with two copies of GPIbb and one of GPIX—the two GPIb-IX heterotetramers are associated with a single copy
of GPV. The cytoplasmic domains of GPIba and GPIbb bind filamin and a number of signal transduction
proteins, including Src (red sphere), 14-3-3 (green), and calmodulin (yellow), and activate PI3-kinase and phos-
pholipase Cg2. (B) GPVI, a receptor for fibrillar collagens, has two Ig domains and is noncovalently associated
with the Fc receptor-g (FcRg) chain, which acts as a signal transduction subunit. On ligand binding, a Src family
kinase (red sphere) phosphorylates two tyrosine residues in the immunoreceptor tyrosine-based activation
motif (ITAM) motif within the FcRg chain. Syk kinase (orange) binds the phosphorylated ITAM motif and acti-
vates phospholipase Cg2. Ca2þ generated downstream from IP3 released by PLC stimulates the Rap-GEF,
CalDAG-GEF1, to activate Rap1, which leads to association of talin-1 with integrins, thereby activating
them. Diacylglycerol (DAG) also induces PKC-mediated release of granule contents, including soluble agonists
and ECM components. (C) Integrins are activated by the VWF and collagen receptors (or by GPCRs bound by
other platelet agonists) through binding of talin-1 and kindlin-3 to their b subunit cytoplasmic domains. Once
activated, integrins can bind their ECM protein ligands. Several b1 integrins are expressed on platelets at a few
thousand copies per platelet, most notably a2b1 and a6b1, receptors for collagens and laminins, respectively,
but alsoa5b1, a receptor for fibronectin and fibrillin andavb3, which binds many ECM proteins (see text). The
major platelet integrin, aIIbb3, is present at 60–80,000 copies per platelet and is the major receptor mediating
platelet aggregation through its binding to fibrinogen (and also to fibronectin, VWF, and several other ECM
proteins—see text). Most integrins bind their ligands (black) through a binding site at the junction between
the head domains of the two subunits—a b propellor domain in the a subunit (dark blue) and a VWA domain
in theb subunit (red). In contrast,a2b1 binds through an additional VWA domain inserted into theb propellor
domain (not shown).
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kininogen, coagulation factors XI and XII,
thrombospondin-1, the integrin Mac-1/
aMb2, and P-selectin. GPIba is a single-pass
transmembrane receptor expressed in high
copy numbers on the platelet surface and is
thought to be constitutively active. Its binding
to the A1 domain of VWF requires arterial shear
rates and is enhanced by increasing shear stress.
As outlined above, this shear dependency is
attributed to a conformational change within
VWF that is required to expose the A1 domain.
Recently solved crystal structures for the unli-
ganded and liganded amino-terminal domain
of GPIba identified an 11-residue sequence
(AA 229–240) within this domain that under-
goes a major conformational change from
an unstructured loop to a b-hairpin (b-switch
region) (Huizinga et al. 2002; Dumas et al.
2004). Interestingly, naturally occurring gain-
of-function (GOF) and loss-of-function (LOF)
mutations also target this region (Russell and
Roth 1993; Moriki et al. 1997; Doggett et al.
2003), suggesting a potential mechanism for
affinity regulation of this receptor. Flow simula-
tions confirmed this hypothesis, as they predict
instability in the b-switch region in unliganded
GPIba, which transitions to a b-hairpin under
conditions of flow (Chen et al. 2008; Lou and
Zhu 2008). GOF or LOF mutations make this
shear-induced switch easier or harder, respec-
tively. Thus, shear stress leads to conformational
changes in both VWF and GPIba.
The importance of both the GPIb-V-IX
receptor and VWF for hemostasis is shown by
the strong bleeding diathesis found in Bernard-
Soulier syndrome (BSS) patients, who lack the
GPIb-V-IX complex on the platelet surface, or
in patients lacking VWF (Bernard and Soulier
1948; Caen et al. 1976; Nurden 1999). Similar
bleeding phenotypes are found for mice defi-
cient in GPIba (Ware et al. 2000) or VWF
(Denis et al. 1998). Interestingly, studies using
transgenic mice indicate that the role of GPIba
exceeds that of VWF in the development of arte-
rial thrombosis, suggesting that one or more of
the other ligands contributes to GPIba function
during thrombus formation (Bergmeier et al.
2006). Thrombus formation in venules, how-
ever, is more dependent on VWF than on
GPIb, which likely reflects the importance of
VWF as a stabilizer of plasma FVIII (Chauhan
et al. 2007). Engagement of GPIb-V-IX leads
to various intracellular changes such as calcium
mobilization, the rearrangement of the cyto-
skeleton, granule release, and activation of the
aIIbb3 integrin (Fig. 3). Numerous cytoplas-
mic binding partners have been described for
GPIba (14-3-3z, filamin, Src family kinases,
phosphatidylinositol-3 kinase, and phospholi-
pase C) and GPIbb (calmodulin and 14-3-3z).
Some of these signal transduction pathways
contribute to the activation of platelet func-
tions, but the exact nature of all the signaling
responses is still unclear (see Fig. 3) (Andrews
et al. 2007; Du 2007).
Integrin aIIbb3
The second major platelet receptor for VWF is
the platelet-specific integrin, aIIbb3, previ-
ously known as glycoprotein GPIIb/IIIa. This
is probably the best-studied integrin and exem-
plifies the most exquisite on-off regulation,
consistent with the requirement for tightly
regulated adhesion in hemostasis (Shattil and
Newman 2004; Bennett et al. 2009). Binding
of the RGD site in the carboxy-terminal region
of VWF by aIIbb3 requires activation of this
integrin, which, unlike GPIb-V-IX, is not con-
stitutively active on resting platelets. Therefore,
engagement of aIIbb3 occurs predominantly
later in the adhesive cascade, during aggrega-
tion, in which it plays an essential role. aIIbb3
is active under both low and high shear condi-
tions, unlike GPIb-V-IX, and the relative
importance of these two receptors for VWF
therefore differs depending on the shear stress.
The crucial importance of aIIbb3 is clear
from the genetic disease, Glanzmann thrombas-
thenia, in which platelets lack this integrin
(Nurden 2006) and from genetically engineered
mice lacking aIIbb3 (Hodivala-Dilke et al.
1999)—both have major bleeding problems
and their platelets fail to aggregate. The molec-
ular details of the interactions of aIIbb3 with
VWF and other ECM ligands during platelet
aggregation will be covered in more detail later
in this article.
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Collagens
Collagens are described in detail by Ricard-
Blum (Ricard-Blum 2011). Fibrillar collagens
are potent activators of GPVI (see below) and
are thus considered strong triggers for throm-
bosis. Interestingly, however, fibrillar collagens
type I, III, and V are found in the deeper layers
of the ECM and are thus not accessible after
superficial injury. Collagens type IV, VIII, and
XVIII are expressed in the basement membrane,
i.e., closer to the endothelial layer. Type IV
collagen forms two-dimensional networks in
the basement membrane rather than fibrils
(Ricard-Blum 2011; Yurchenco 2011), and
based on in vitro studies (Jung et al. 2008), is
thought to be considerably less potent than
fibrillar collagens with regard to engaging
GPVI or binding VWF. Studies in vivo, however,
suggest that type IV collagen triggers GPVI-
dependent thrombosis induced by superficial
injury to the vessel wall (Hechler et al. 2010),
confirming earlier studies that indicated a
supportive role for collagen type IV in platelet
adhesion and thrombosis at low and high
shear rates (Henrita van Zanten et al. 1996;
Jarvis et al. 2002).
As outlined above, VWF binding to collagen
is an early step in the adhesion cascade follow-
ing vascular damage. The A3 domain has been
identified as the most critical domain within
VWF for this interaction to occur, and inhibi-
tors of this domain have proven beneficial in
reducing thrombosis in animals (Deckmyn
et al. 2005). Platelets then roll along the depos-
ited VWF, allowing collagen-specific platelet
receptors to engage.
GPVI Receptor
GPVI is a 60–65 kDa type I transmembrane gly-
coprotein belonging to the immunoglobulin
superfamily of adhesion receptors (Clemetson
and Clemetson 2001; Nieswandt and Watson
2003; Jung and Moroi 2008). It contains two
immunoglobulinlike domains (D1 and D2),
which are connected with the transmembrane
and cytoplasmic domain via a mucinlike stalk
(see Fig. 3). GPVI is noncovalently associated
with the Fc receptor (FcR) g chain, which serves
as the signal-transducing subunit of the recep-
tor in human as well as mouse platelets. GPVI-
deficient patients suffer from a mild bleeding
diathesis, and their platelets respond poorly to
collagen or collagen mimetics (Moroi et al.
1989; Arai et al. 1995; Dumont et al. 2009; Her-
mans et al. 2009). Platelets from GPVI-deficient
mice (Kato et al. 2003) also fail to respond to
collagen, although they show a normal response
to stimulation via GPCRs. The GPVI crystal
structure suggests that the ligand-binding
site resides within the D1 domain and that
the D2 domain facilitates the dimerization of
the receptor required to support ligand bind-
ing (Horii et al. 2006). Engagement of GPVI
further requires repetitive Gly-Pro-Hyp se-
quences within the collagen fiber, which facilitate
the clustering of the receptor on the cell surface
(Knight et al. 1999). Signaling downstream
from GPVI occurs via a similar pathway to that
used by immunoreceptors (Nieswandt and Wat-
son 2003), initiated by the tyrosine phosphory-
lation of the FcR g-chain immunoreceptor
tyrosine-based activation motif (ITAM) by a
Src-like kinase (Fyn or Lyn). The signaling
events directly downstream from binding of Syk
to the tyrosine-phosphorylated ITAM of the
FcR g-chain orchestrate the activation of phos-
pholipase Cg2, leading to the generation of
the second messengers, diacylglycerol (DAG)
and calcium (see Fig. 3). The guanine nucleo-
tide exchange factor, CalDAG-GEFI (RasGRP2),
senses increased intracellular calcium concen-
trations and regulates various platelet responses
via activation of the small GTPase Rap1 (Crit-
tenden et al. 2004; Stefanini et al. 2009). DAG
itself induces the activation of protein kinase
C, a key regulator of platelet granule release
and thus critical for positive feedback activation
of the cell (Harper and Poole 2010). Down-
stream from Rap1, talin-1 (Nieswandt et al.
2007; Petrich et al. 2007) and kindlin-3 (Moser
et al. 2008) bind to the cytoplasmic tail of integ-
rins, thereby facilitating inside-out activation of
these adhesion receptors and firm platelet adhe-
sion to the collagen/VWF matrix (Campbell
and Humphries, 2011; Wickstrom et al, 2011).
GPVI signaling is also critical for the platelet
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procoagulant response, i.e., the ability of acti-
vated platelets to promote clotting (Heemskerk
et al. 1999; Dale 2005). Signaling via GPVI,
unlike that initiated by engagement of GPCRs,
leads to a sustained increase in intracellular cal-
cium levels required for the disruption of the
asymmetry of the lipid bilayer. The resulting
surface exposure of negatively charged phos-
phatidylserine provides a catalytic surface for
the assembly of plasma clotting factors and
thus catalyzes the generation of the fibrin clot
(see below).
Integrin a2b1
Firm attachment of platelets to collagen is
mediated by integrin a2b1 and indirectly by
integrin aIIbb3 binding to collagen-bound
VWF (see above). Compared to aIIbb3, a2b1
integrin is expressed on platelets at low copy
numbers (2000–4000 copies per platelet);
however, its surface expression level can vary
up to 10-fold between individuals owing
to the C807T genetic polymorphism of a2
(Kunicki et al. 1997). Like other integrins,
a2b1 is expressed on resting platelets in a
low-affinity state (Nuyttens et al. 2011). Upon
cellular activation, the extracellular domains of
both subunits extend upwards and the integrin
shifts to a high-affinity state. Critical for colla-
gen binding to a2b1 is an I domain inserted
into the b-propeller domain of the a2 subunit.
The I domain is a VWA domain homologous
with the collagen-binding A3 domain in
VWF. Both these domains contain a conserved
metal-ion-dependent adhesion site (MIDAS)
involved in the binding of collagen. Within
the collagen molecule, GFOGER sequences (in
which O stands for hydroxyproline) were iden-
tified as the high-affinity binding site for
a2b1—the glutamate residue (E) coordinates
the metal ion in the MIDAS site (Emsley et al.
2000).
Early studies with platelets from patients
with a deficiency in a2b1 suggested that this
integrin plays a central role in sensing exposed
collagen fibrils (Nieuwenhuis et al. 1985; Kehrel
et al. 1988). However, the relationship between
the clinical symptoms and the proposed a2b1
deficiency was later questioned (Nieswandt
and Watson 2003), as studies in genetically
modified mice showed a key role for GPVI but
not for a2b1 in collagen-induced platelet acti-
vation (Nieswandt et al. 2001). These results
were partially confirmed under physiological
flow conditions ex vivo and in vivo, in which
deficiency in a2b1 provided only limited
or no protection from thrombosis (Nuyttens
et al. 2011). Based on these studies, a model
in which a2b1 contributes to the stability of
collagen-induced thrombi by (1) anchoring
the first layer of platelets to the collagen surface
and (2) contributing to GPVI-mediated platelet
activation, has emerged. Consequently, im-
paired a2b1 expression/function results in
thrombus instability, most likely because of
the important role of a2b1 outside-in signaling
in the generation of the second-wave mediator
thromboxane A2 (Kuijpers et al. 2007; Stefanini
et al. 2009).
Laminins and Laminin Receptors
Laminins are heterotrimeric glycoproteins con-
sisting of a, b, and g chains (Yurchenco 2011).
Basement membranes of all blood vessels pre-
dominantly express a4 or a5 laminin subtypes
(Hallmann et al. 2005). Platelets express at least
three receptors, which directly interact with
laminin: integrin a6b1 (Ill et al. 1984; Sonnen-
berg et al. 1988), GPVI (Inoue et al. 2006; Ozaki
et al. 2009), and an uncharacterized 67 kDa pro-
tein (Tandon et al. 1991; Nelson et al. 2008). So
far, only the roles of a6b1 integrin and GPVI in
platelet adhesion to laminin are well docu-
mented. Interestingly, the processes mediating
platelet adhesion to laminin are similar to those
regulating platelet-collagen interactions. Under
arterial flow conditions, platelet adhesion to
laminin requires an initial adhesion step medi-
ated by the GPIba-VWF interaction. However,
binding of a6b1 to laminin is a prerequisite
for binding of GPVI, whereas binding of a2b1
to collagen predominantly occurs as a response
to engagement of GPVI by collagen. This differ-
ence may be explained by the 10-fold lower
affinity of GPVI for laminin when compared
with collagen (Inoue et al. 2006). The inability
Extracellular Matrix Proteins in Hemostasis and Thrombosis
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of laminin to induce platelet aggregation in sus-
pension is likely also the result of this lower
affinity. In the absence of GPVI, platelets adhere
normally to laminin but fail to spread properly.
So far, it is not clear if the platelet-laminin
interaction provides a critical contribution to
thrombosis and hemostasis. Compared to colla-
gen, laminin seems to be a weak platelet agonist.
Thus, exposure of collagen in the deeper layers
of the extracellular matrix will likely mask any
role of laminin in the basement membrane.
Superficial injuries, however, will not expose
fibrillar collagens, and under these conditions,
laminin-mediated adhesion may be more im-
portant.
As noted earlier, platelets can be exposed to
a wide variety of ECM protein ligands, depend-
ing on the situation (see Fig. 1). While VWF and
collagen are the main agonistic ligands, binding
as they do to constitutively active receptors
(GPIb-V-IX and GPVI, respectively) and sub-
sequently to activated integrins (aIIbb3 and
a2b1, respectively), platelets also express other
ECM receptor integrins at levels comparable
to their levels of a2b1 (Varga-Szabo et al.
2008). These other integrins are a5b1, a recep-
tor for fibronectin and fibrillin, and avb3, a
promiscuous receptor that can bind almost
any ECM protein containing an exposed
RGD motif (e.g., thrombospondin, vitronectin,
nidogens, fibronectin, and fibrillin, as well as
the major platelet ligands, VWF and fibrino-
gen). It is currently unclear what role these
integrins, which presumably require activation,




For the hemostatic plug to form, additional cir-
culating platelets need to be incorporated into
the growing thrombus. Initially, recruitment
of additional platelets depends on mechanisms
similar to those that regulate platelet adhesion
to the ECM. Transient adhesion under elevated
shear stress (arterial shear rates) requires the
interaction of GPIba with one of its ligands,
most prominently VWF (Kulkarni et al. 2000;
Bergmeier et al. 2006). At low shear conditions
(venous shear rates), however, platelet adhesion
does not depend on GPIba, and platelet aggre-
gation is largely dependent on the major platelet
integrin, aIIbb3 (Savage et al. 1996; Chauhan
et al. 2007). Firm platelet–platelet cohesion
and aggregation requires activation of integrin
aIIbb3, which is present at 60–80,000 copies
per platelet (Hynes 2002; Bennett et al. 2009;
Li et al. 2010). On resting platelets, aIIbb3 is
in an inactive state and does not bind any
ligands. However, activation of platelets by sig-
naling from GPIb-V-IX or GPVI/FcgR (see
Fig. 3) or by soluble agonists such as thrombin,
the product of the clotting cascade, or ADP and
thromboxane A2, so-called second-wave medi-
ators released by already activated platelets,
causes “inside-out” activation of aIIbb3. Its
subsequent interaction with ECM ligands
deposited on the surface of the growing throm-
bus leads to platelet aggregation and formation
of an occlusive thrombus. The major ligand for
aIIbb3 is fibrinogen, present in plasma at 2–
4 mg/ml (10 mM). The major binding site
foraIIbb3 is a KQGADV sequence near the car-
boxyl terminus of the g chain of fibrinogen.
Other known ligands for aIIbb3 include VWF,
fibronectin, thrombospondin, and vitronectin,
all of which contain RGD sequences critical
for binding to aIIbb3 integrin. Studies using
mouse models of thrombosis have implicated
all of these ECM proteins to one degree or
another in formation of stable platelet aggre-
gates in vivo (Denis and Wagner 2007; Maurer
et al. 2010)
The platelet thrombus is further stabilized by
the engagement of additional receptor-ligand
pairs, such as Gas-6 and its receptors (Tyro3,
Axl, and Mer), ephrin and Eph receptor kinases,
or CD40 ligand and aIIbb3 integrin (Brass et al.
2006). Many of these interactions, like those ini-
tiating platelet activation (discussed above) lead
to activation of aIIbb3 integrin by inside-out
signaling (cf. Fig. 3). Once activated and engaged
by ligand, aIIbb3, like other integrins, also
mediates outside-in signaling that further
enhances platelet adhesion and aggregation
(Shattil and Newman 2004). Finally, clot stabil-
ity is greatly increased by the fibrin network,
W. Bergmeier and R.O. Hynes
10 Cite this article as Cold Spring Harb Perspect Biol 2012;4:a005132
the result of the intrinsic and/or extrinsic activa-
tion of the coagulation cascade to cleave fibrino-
gen to fibrin (see below).
RELATIVE CONTRIBUTION OF INDIVIDUAL
PLATELET RECEPTORS AND ECM
COMPONENTS TO THROMBOSIS
AND HEMOSTASIS
The critical contributions of GPIb-V-IX and
aIIbb3 integrin to arterial thrombosis are well
documented (Nurden 1999; Ruggeri 2002).
Patients with defective expression of either
receptor suffer from a markedly increased risk
of bleeding. These hemostatic defects can be
recapitulated in mice by genetic deletion of
the respective receptors (Hodivala-Dilke et al.
1999; Ware et al. 2000). These mice are also
strongly protected in various models of throm-
botic disease, including localized thrombosis in
the micro- and macrocirculation and ischemic
stroke (Stegner and Nieswandt 2011). In con-
trast, patients with a deficiency in GPVI show
only a mild bleeding phenotype (Moroi et al.
1989; Arai et al. 1995; Dumont et al. 2009; Her-
mans et al. 2009). Consistent with this finding,
mice lacking GPVI are characterized by an
almost normal hemostatic response (Kato
et al. 2003). When tested in experimental mod-
els of thrombotic disease, these mice show var-
ious degrees of protection, a finding that is likely
a reflection of the collagen dependencies of the
thrombosis models (Dubois et al. 2006; Hechler
et al. 2010). Mice deficient in a2 integrins or
lacking allb1 integrins on platelets showed little
protection from experimental thrombosis and
are not susceptible to bleeding (Nuyttens et al.
2011). Importantly, however, infusion of a
GPVI-blocking antibody markedly increased
the bleeding risk in a2-deficient mice, suggest-
ing that the importance of a2b1 is masked by
GPVI, and that these two receptors have par-
tially redundant functions (Gruner et al. 2004).
Redundancy was also observed in studies on
the prothrombotic role of individual matrix
components. Mice deficient in VWF are charac-
terized by reduced platelet adhesion to the
ECM, a delayed onset of thrombus formation,
and the formation of almost occlusive thrombi
that nonetheless retain open channels, presum-
ably because of the requirement for VWF for
effective platelet recruitment at high shear stress
(Denis et al. 1998; Ni et al. 2000). This pheno-
type is less severe than that observed in mice
with impaired GPIba expression (Bergmeier
et al. 2006), suggesting that other GPIba ligands
such as thrombospondin-1 may partially com-
pensate for VWF. In contrast, thrombi form
rapidly in mice lacking fibrinogen, but these
thrombi are not firmly anchored to the vessel
wall and thus frequently embolize (Ni et al.
2000; Jirouskova et al. 2004). Deficiency in
plasma fibronectin, on the contrary, delays for-
mation of occlusive thrombosis because the
developing thrombi continually shed platelets,
possibly owing to a role for fibronectin in stabi-
lizing platelet–platelet interactions in the grow-
ing thrombus (Ni et al. 2003; Cho and Mosher,
2006; Matuskova et al. 2006;). An alternative
possibility is that the absence of fibronectin,
which normally becomes cross-linked to fibrin
in the forming clot through the action of factor
XIII transglutaminase, leads to reduced platelet-
fibrin interactions or to a friable fibrin clot.
Interestingly, mice lacking both VWF and fibri-
nogen (Ni et al. 2000) or all three of VWF, fibri-
nogen, and plasma fibronectin (Reheman et al.
2009), are still able to form thrombi, albeit less
well. Thus, there is substantial redundancy
among individual matrix components in their
ability to promote thrombosis and hemostasis.
It seems likely that the relative contributions
of the different ECM ligands may well differ
depending on the degree of injury and the type
of vessel involved. As noted earlier and in Fig-
ure 1, the diversity of ECM ligands available
varies greatly among vessels and is further altered
in disease states. As one example, fibronectin
levels and inclusion of the alternatively spliced
segments, EIIIA and EIIIB, increase in athero-
sclerotic plaques, in vessel walls after myocardial
infarction, and in cancer (Astrof and Hynes,
2009), and mice engineered to express EIIIAþ
fibronectin in their plasma, in which it is nor-
mally absent, show enhanced thrombosis
(Chauhan et al. 2008). It is therefore plausible
that the ability of platelets to recognize diverse
ECM ligands may lead to differences in the
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strength of the thrombotic response in disease
states. This issue needs further investigation.
CELLULAR INTERACTIONS WITH
THE FIBRIN CLOT: RETRACTION
AND WOUND HEALING
Once the fibrin clot has formed, with activated
platelets incorporated into and onto it and
frequently with other cells (erythrocytes, leuko-
cytes) associated with it, the clot serves as the
substrate for subsequent wound healing. Fibrin
is essentially a neomatrix or facultative matrix
induced by the processes of thrombosis and
coagulation. Platelets embedded in the clot are
attached to the fibrin via activated integrin
aIIbb3 that is, in turn, linked to the cytoskele-
ton. Like other integrin-cytoskeleton connec-
tions, the aIIbb3-fibrin linkage can exert force
leading to clot retraction. Based on studies
with Glanzmann thrombasthenia patients
(Nurden 2006) and with mice lacking aIIbb3
(Hodivala-Dilke et al. 1999), clot retraction is
fully dependent on this integrin. Contraction
of the clot closes the lesion in the blood vessel
that has been occluded by the clot and can
also contribute to broader wound closure.
However, much of that subsequent closure
relies on other cells recruited to the damaged
area, as does subsequent resorption of the clot.
Those recruited cells rely on the so-called provi-
sional fibrin matrix for their ability to migrate
into the wound region. Key among the cells
involved in wound repair are fibroblastic cells
and leukocytes. The fibrin clot includes other
ECM proteins, most notably fibronectin cross-
linked by factor XIII, which is crucial for fibro-
blast migration into the clot (Hynes, 1990). The
fibroblasts become transformed into contractile
myofibroblasts, at least in part under the influ-
ence of TGF-b, which is rich in clots, probably
mostly provided by the platelets, which are
major sources of this factor (Assoian and Sporn
1986). TGF-b up-regulates synthesis of many
ECM proteins, including interstitial collagen
and fibronectin, and induces inclusion of the
alternatively spliced fibronectin domains EIIIA
and EIIIB (Leask and Abraham 2004). It is per-
haps of some interest that, although plasma
fibronectin lacks these two spliced segments,
platelet fibronectin, which is released from a
granules on platelet activation does include
them (Hynes 1990). The exact functions of
these splice segments in wound healing remain
unclear but they are necessary for proper vascu-
lar development and may play a role in angio-
genesis (Astrof et al. 2007; Astrof and Hynes
2009). It is clear that the new ECM formed
during the hemostatic response and deposited
in the wound bed is an important part of the
overall process of wound closure. Although
the platelets contribute the initial clot retrac-
tion, the subsequent retraction of the wound
ECM is accomplished by the fibroblasts
recruited to the provisional fibrin-rich matrix
laid down during thrombosis. However, the
TGF-b contributed by the platelets and the
provisional ECM of the clot play key roles in
generating the granulation tissue (ECM and
fibroblasts).
The seeds of clot dissolution are also incor-
porated during the initial thrombotic process.
Tissue plasminogen activator (tPA) has a rela-
tively high affinity for fibrin, to which it binds
through an FN1 domain homologous with the
fibrin-binding domains of fibronectin. Because
of this, tPA becomes incorporated into the clot
(Medved and Nieuwenhuizen 2003). Subse-
quent activation of plasminogen to active plas-
min by the tPA is key to the dissolution of the
clot. The high affinity of tPA for fibrin clots
forms the basis for its use as a “clot buster,” ther-
apeutic in cases of myocardial infarction and
stroke.
Incorporation or recruitment of leukocytes
into the clot and the subsequent provisional
and wound healing matrices requires their affin-
ity for those matrices. The integrin aMb2 (also
known as Mac-1, CR3, or CD11bCD18) and its
sister, aXb2, both recognize and bind fibrin
(Wright et al. 1988; Loike et al. 1991). aMb2
also acts as a chemotactic receptor to fibrin deg-
radation products. Migration of leukocytes into
the provisional and wound matrices provides
a source of cells, specialized to degrade and
remove these matrices because these cells pro-
duce multiple proteolytic enzymes and are
actively phagocytic.
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CONCLUDING REMARKS
The detailed understanding of the adhesion and
aggregation mechanisms of platelets has already
provided many effective antithrombotic drugs
targeting either the activation pathways neces-
sary for inside-out activation of aIIbb3 for
binding of its ECM ligands or the multiple
receptor-ECM interactions mediating platelet
adhesion and aggregation, and further studies
underway show promise for additional thera-
peutic interventions.
Antiplatelet drugs already in clinical use
target (1) the generation of the second-wave
mediator thromboxane A2 (aspirin), (2) posi-
tive feedback activation by the second-wave medi-
ator ADP (clopidogrel, prasugrel), and (3) the
major platelet integrin, aIIbb3 (ReoPro, Integ-
rilin, Aggrastat).
Aspirin and clopidogrel/prasugel are orally
deliverable and suitable for routine preventive
dosing against thrombotic events. The drugs
targetingaIIbb3 are all injectables and are com-
monly used to prevent reocclusion after angio-
plasty. Drugs directed against several other
platelet proteins are in (pre)clinical evaluation
(De Meyer et al. 2008; Siller-Matula et al.
2010). These include inhibitors of the thrombin
receptor PAR1, the GPCR receptors for throm-
boxane, and the ECM receptors GPVI and
GPIba. In fact, several strategies to disrupt the
VWF-GPIba interaction are currently under
investigation: (1) direct inhibitors of GPIba,
(2) inhibitors targeting the A1 domain of
VWF, (3) molecules that disrupt the interaction
of collagen with the A3 domain in VWF, and (4)
recombinant ADAMTS-13 as an attempt to
lower the adhesiveness of VWF. The success of
these novel interventions will depend on their
ability to reduce the risk of thrombotic compli-
cations without markedly increasing the risk of
bleeding in the patient.
The identification of new targets for safe in-
terventions against atherothrombosis strongly
depends on studies in animal (mouse) models
of thrombosis. One of the various limitations
of this approach, however, arises from the fact
that thrombosis has typically been studied in
otherwise healthy vessels, i.e., on an exposed
ECM that is likely much different from that
found on a ruptured atherosclerotic plaque,
which is known to contain altered ECM (e.g.,
collagens, fibrin, fibronectins). To address this
shortcoming and to develop better models of
atherothrombotic events, several laboratories
have now started to evaluate thrombosis in
apoE-deficient mice, which develop athero-
sclerotic plaques and in which plaque rupture
can be induced mechanically or by ultrasound
treatment (Kuijpers et al. 2009; Hechler and
Gachet 2011). Alternatively, adhesion of human
platelets is studied in human blood perfused
over homogenized plaque material (Cosemans
et al. 2005; Penz et al. 2005; Schulz et al. 2008;
Reininger et al. 2010). The results from these
studies confirm the predicted concomitant
involvement of collagen-induced platelet acti-
vation and tissue factor-triggered thrombin
generation and fibrin formation. As in other
thrombosis models, the collagen-GPVI interac-
tion seems to be prominent after mild injury
to the plaque (induced by ultrasound), whereas
plaque rupture causes a more thrombin-
dependent response. Thus, studying thrombo-
sis on the ruptured/homogenized plaque mate-
rial may become a new gold standard for the
validation of novel antithrombotic targets.
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